Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers
Rosa Polo, Xabier García‐Albéniz, Carolina Terán, Miguel Morales, David Rial‐Crestelo, María Ángeles Garcinuño, Miguel García Deltoro, César Hita, Juan Luís Gómez-Sirvent, Luís Buzón, Alberto Díaz de Santiago, Jose Pérez Arellano, Jesús Sanz, P Bachiller, Elisa Martínez Alfaro, Vicens Díaz-Brito, Mar Masiá, Alicia Hernández‐Torres, María José Guerra Palmero, Jesús Santos, Piedad Arazo, Leopoldo Muñoz, José Ramón Arribas, Pablo M. De Salazar, Santiago Moreno, Miguel A. Hernán, Julia Del Amo, Julia del Amo, Rosa Polo, Santiago Moreno, Juan Berenguer, Estebán Martínez, Miguel A. Hernán, Pablo M. De Salazar, Xabier García de Albéniz
Topics & Concepts
EmtricitabineHydroxychloroquineMedicinePre-exposure prophylaxisPlaceboCoronavirus disease 2019 (COVID-19)Randomized controlled trialTenofovirSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Double blind2019-20 coronavirus outbreakInternal medicineVirologyHuman immunodeficiency virus (HIV)Alternative medicineViral loadAntiretroviral therapyMen who have sex with menPathologyOutbreakDiseaseSyphilisInfectious disease (medical specialty)COVID-19 Clinical Research StudiesInfectious Encephalopathies and EncephalitisLong-Term Effects of COVID-19